RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:RARE

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/26	21:00	GlobeNewswire Inc.	Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/09/19	06:00	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/09/19	02:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/09/06	00:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/08/30	05:30	GlobeNewswire Inc.	Ultragenyx to Participate in Investor Conferences in September	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/08/23	20:00	Business Wire	Tactical Resources, a Growing North American Rare Earth Elements Company, to List on NASDAQ	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/08/22	05:30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/08/02	05:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/08/02	05:05	GlobeNewswire Inc.	Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/07/26	05:05	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/07/24	21:00	GlobeNewswire Inc.	Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/07/20	05:05	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/07/18	05:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/07/18	05:05	GlobeNewswire Inc.	Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/07/13	05:04	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/21	05:30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/21	03:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/21	03:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/21	03:22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/17	19:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/15	06:11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/14	09:49	GlobeNewswire Inc.	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	08:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	06:20	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	06:10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	05:05	GlobeNewswire Inc.	Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	05:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/13	05:00	GlobeNewswire Inc.	Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/12	06:47	GlobeNewswire Inc.	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/06/11	08:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc